Get the Stockscreener App
14.40
2.49%
0.35
Pre-market:
14.39
-0.010
-0.07%
Prothena Corporation Plc stock is traded at $14.40, with a volume of 618.63K.
It is up +2.49% in the last 24 hours and down -15.84% over the past month.
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
See More
Previous Close:
$14.05
Open:
$14.05
24h Volume:
618.63K
Relative Volume:
1.30
Market Cap:
$774.31M
Revenue:
$217.25M
Net Income/Loss:
$-50.92M
P/E Ratio:
-10.14
EPS:
-1.42
Net Cash Flow:
$-100.85M
1W Performance:
-16.42%
1M Performance:
-15.84%
6M Performance:
-36.37%
1Y Performance:
-57.77%
1-Day Range:
$13.49
$14.58
1-Week Range:
$13.22
$17.93
52-Week Range:
$13.22
$41.55
Prothena Corporation Plc Stock (PRTA) Company Profile
Name
Prothena Corporation Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| PRTA | 14.40 | 774.31M | 217.25M | -50.92M | -100.85M | -1.42 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corporation Plc Stock (PRTA) Latest News
Prothena (NASDAQ:PRTA) Rating Lowered to “Sell” at StockNews.com - Defense World
Prothena FY2024 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Prothena FY2024 EPS Forecast Boosted by Cantor Fitzgerald - MarketBeat
FY2024 EPS Estimates for Prothena Reduced by HC Wainwright - MarketBeat
Prothena (NASDAQ:PRTA) Hits New 12-Month LowHere's What Happened - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Receives $61.86 Average PT from Brokerages - Defense World
FY2028 EPS Estimates for Prothena Increased by HC Wainwright - MarketBeat
Prothena's SWOT analysis: stock poised for potential breakthroughs amid risks - Investing.com India
Expert Ratings For Prothena Corp - Benzinga
Prothena's (PRTA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Prothena (NASDAQ:PRTA) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus - Yahoo Finance
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights - BioSpace
Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Prothena: Q3 Earnings Snapshot - Marketscreener.com
Prothena Corp PLC Reports Q3 2024 EPS Loss of $1.10, Beats Estimate; Revenue Misses at $1.0 Million - GuruFocus.com
Prothena Reports $59M Q3 Loss, Pipeline Updates Signal Key Trial Results in 2024-25 | PRTA Stock News - StockTitan
Prothena Corporation plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Prothena Co. plc (NASDAQ:PRTA) Receives $61.86 Average Target Price from Brokerages - MarketBeat
Creative Planning Invests $350,000 in Prothena Co. plc (NASDAQ:PRTA) - Defense World
Wellington Management Group LLP's Strategic Acquisition in Proth - GuruFocus.com
Prothena (PRTA) Scheduled to Post Earnings on Tuesday - MarketBeat
Prothena to Report Third Quarter 2024 Financial Results on November 12 - The Bakersfield Californian
Long Term Trading Analysis for (PRTA) - Stock Traders Daily
Prothena (NASDAQ:PRTA) Stock Price Up 5.7%Here's Why - MarketBeat
Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength? - Yahoo Finance
Prothena (NASDAQ:PRTA) Shares Gap UpShould You Buy? - MarketBeat
Prothena's SWOT analysis: stock poised for growth amid clinical milestones - Investing.com
Prothena Co. plc (NASDAQ:PRTA) Short Interest Up 28.1% in October - MarketBeat
Prothena (NASDAQ:PRTA) Sets New 12-Month LowHere's What Happened - MarketBeat
When (PRTA) Moves Investors should Listen - Stock Traders Daily
SG Americas Securities LLC Sells 40,485 Shares of Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Analysts Set Prothena Co. plc (NASDAQ:PRTA) Target Price at $61.86 - Defense World
State Street Corp's Strategic Reduction in Prothena Corp PLC Hol - GuruFocus.com
Prothena: Delays And Data Uncertainty Undermine Case For Investing (Downgrade) (PRTA) - Seeking Alpha
Prothena Co. plc (NASDAQ:PRTA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Prothena (NASDAQ:PRTA) Stock Price Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat
Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
(PRTA) Long Term Investment Analysis - Stock Traders Daily
Is Prothena Corporation plc (PRTA) worth investing in despite its undervalued state? - US Post News
Holdings of Prothena Corporation plc (PRTA) are aligned with the stars - SETE News
Daily Progress: Prothena Corporation plc (PRTA) Gain 0.36, Closing at 16.86 - The Dwinnex
Dimensional Fund Advisors LP Reduces Holdings in Prothena Co. plc (NASDAQ:PRTA) - Defense World
Duncan Williams Asset Management LLC Makes New Investment in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Algert Global LLC Acquires 28,841 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Nothing is Better Than Prothena Corporation plc (PRTA) stock at the moment - SETE News
(PRTA) On The My Stocks Page - Stock Traders Daily
Prothena Corporation plc (NASDAQ:PRTA) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough - Simply Wall St
PRTA’s price-to-sales ratio: A comparative analysis with its peers - US Post News
Prothena Corporation plc (PRTA) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Prothena Corporation Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):